Royalty Pharma — 1 certified H-1B filings (FY2026)

1
Filings · FY2026
$175k
Median base · FY2026
Senior Analyst
Top role · 1 all-time
NY
Top state · 1 all-time

Royalty Pharma filed 1 certified H-1B LCAs in FY2026, with a median base salary of $175k and the middle 50% of offers between $175k and $175k. Across all years it has 1 certified filings since FY2026, most often for Senior Analyst in New York.

How much does Royalty Pharma pay H-1B workers?

Certified base salary by fiscal year: each box is the p25–p75 range, the heavy line the median, the whiskers reach p10–p90. $175k median in FY2026. Base pay only — hover a year for its figures.

$160k$170k$180k$190k’26

How has Royalty Pharma's H-1B hiring changed by year?

1 certified filings on record (FY2026).

Royalty Pharma certified H-1B filings and base salary by fiscal year
Fiscal yearFilingsvs prior FYMedian base
FY20261—$175k

Which wage levels does Royalty Pharma file?

DOL prevailing-wage levels I–IV approximate experience tiers (I = entry, IV = fully competent). 100% of Royalty Pharma's filings sit at Level III–IV. A heavy I–II skew reads as entry-level or contractor-style hiring; a heavy IV skew as senior in-house roles — and higher levels earn more lottery entries.

Share of 1 filings with a wage level · all years

100%
  • Level III100.0%1

What jobs does Royalty Pharma sponsor for H-1B?

The most-filed job titles across all years (DOL titles, employer pay-grade codes stripped), with base-salary percentiles.

Royalty Pharma most-sponsored H-1B job titles with base-salary percentiles
Job titleFilingsMedian base
Senior Analyst1$175k

Where does Royalty Pharma hire H-1B workers?

Worksite states on the certified filings, all years. Deeper pink = more filings; hover a state for its figures.

11Certified filings (log scale)
Royalty Pharma H-1B worksite states
StateFilingsMedian base
NY1$175k

What has Royalty Pharma filed recently?

Every certified LCA on record for Royalty Pharma: job title, worksite, prevailing-wage level and the offered base salary.

Royalty Pharma recent certified H-1B LCA filings
FYJob titleBase salary
2026Senior Analyst$175,000

Common questions about Royalty Pharma's H-1B filings

How much does Royalty Pharma pay H-1B workers?
Royalty Pharma's median certified H-1B base salary is $175k (FY2026), from 1 filings. See the full salary distribution and percentiles above.
How many H-1B workers does Royalty Pharma sponsor?
Royalty Pharma has 1 certified H-1B Labor Condition Applications on record (FY2026).
What jobs does Royalty Pharma sponsor for H-1B?
Royalty Pharma's most-sponsored H-1B roles include Senior Analyst.
Where does Royalty Pharma hire H-1B workers?
Royalty Pharma's top H-1B worksite states are NY.
Does a certified LCA mean an H-1B visa was approved?
No. A Labor Condition Application (LCA) is the Department of Labor attestation an employer must have certified before filing an H-1B petition with USCIS. It records the job, worksite and offered wage, but not whether the petition was filed, selected in the lottery, or approved. Filing counts measure intent to sponsor, not headcount.
What salary do these figures show?
The base annual wage offered on the certified LCA, converted to a yearly amount. Bonus, equity, overtime and benefits are not included, so total compensation is typically higher. Figures are medians and percentiles over certified filings; wages above $5,000,000 a year are excluded as data-entry errors.
What do prevailing-wage levels I–IV mean?
The Department of Labor assigns each LCA an OES wage level from I (entry) to IV (fully competent) for the occupation and area. Under the FY2027 wage-weighted H-1B lottery rule, a higher level earns more selection entries, so an employer's level mix is a proxy for how senior its sponsored roles are.

Keep exploring

Browse all sponsors →

Calculate your H-1B lottery odds →orCheck out the insights →

Source: U.S. Department of Labor, Office of Foreign Labor Certification — certified LCA disclosure data through June 2026 (FY2026). An LCA is not an approved visa; pay figures are base salary and exclude bonus and equity. Methodology →